Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.

Date publication

mars 2018

Journal

The lancet. HIV

Auteurs

Membres identifiés du Cancéropôle Est :
Dr WIRTH Nathalie

Tous les auteurs :
Mercié P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Bénard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chêne G,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29329763

Résumé

Tobacco smoking is common in people living with HIV, but high-quality evidence on interventions for smoking cessation is not available in this population. We aimed to assess the efficacy and safety of varenicline with counselling to aid smoking cessation in people living with HIV.

Mots clés

Adult, Counseling, Double-Blind Method, Drug Administration Schedule, Female, France, HIV Infections, complications, Humans, Male, Middle Aged, Nicotinic Agonists, administration & dosage, Smoking, drug therapy, Treatment Outcome, Varenicline, administration & dosage

Référence

Lancet HIV. 2018 03;5(3):e126-e135